Skip to main content

Table 2 Clinical characteristics of the 34 studies included in the meta-analysis

From: Risk of second breast cancer in female Hodgkin’s lymphoma survivors: a meta-analysis

Author & Year Country Year Design Source of data STROBE criteria (met/applicable) RT only No. (%) CTX only No. (%) RT-CTX No. (%) Comments
Coleman 1987 [23] UK 1961-1980 PBCS. Cancer registry 25/32 (35–36) (20–28) (27–34) Therapy data for M + F HL patients. Number NR.
Hancock 1993 [24] USA 1961–1989 Single institution cohort study Computerized database and patient records 24/31 383 (43) 30 (3) 341 (39) Therapy data for M + F HL patients. 15% did not receive any treatment.
Wolden 1998 [30] USA 1960-1995 Single institution cohort study (HL Dx. ≤21y) Computerized database and patient records 22/31 144 (47) 9 (3) 154 (50) Therapy data for female patients
Wolden 2000 [37] USA 1960-1997 Single institution retrospective review Computerized database and patient records 24/32 37 (57) 1 (2) 27 (41) Therapy data for SBC patients. 27 patients received alkylating CTX.
O'Brien 2010 [58] USA 1970-1990 Single institution study of children Retrospective chart review and patient questionnaires 23/31 0 (0) 0 (0) 35 (100) Therapy data for M + F pediatric HL patients. All received low-dose RT and alkylating CTX.
van Leeuwen 1994 [25] Netherlands 1966-1986 2 institutions cohort study Institutional registries and patient records 22/30 552 (29) 178 (9) 1209 (62) Therapy data for M + F HL patients. All SBC received RT.
De Bruin 2009 [55] Netherlands 1965-1995 6 institutions cohort study (5y survivors) Medical records, and physician questionnaires 25/32 357 (31.8) 80 (7.1) 685 (61.1) Therapy data for all HL female patients
Mauch 1996 [26] USA 1969-1988 5 institutions cohort study Institutional records 25/31 489 (62) 0 (0) 305 (38) Therapy data for M + F HL patients
Ng 2002 [41] USA 1969–1997 4 institutions cohort study Institutional records 26/32 665 (69) 0 (0) 296 (31) Therapy data for M + F HL patients
Sankila 1996 [27] Nordic countries 1940-1987 5 Nordic PBCS (HL Dx. ≤20y) National cancer registries 21/31 NR NR NR All SBC patients received RT
Metayer 2000 [36] USA and Europe 1935–1994 16 PBCS (HL Dx. ≤21y, 1-year survivors) National cancer registries 22/32 NR NR NR  
Hodgson 2007 [48] USA and Europe 1970-2001 13 PBCS (5-year survivors) National cancer registries 22/32 6461 (34) 145 (74) 4398 (23) 26 (13) 2847 (15) 36 (18) First raw: therapy data for M + F HL patients. (27% with unknown treatment). Second raw:therapy data for SBC patients (28% with unknown treatment)
Dores 2010 [57] USA 1973-2000 9 PBCS (5-year survivors, Dx. ≤35y) 9 cancer registry areas of SEER 22/32 NR NR NR All patients had RT
Aisenberg 1997 [28] USA 1964-1984 Single institution cohort study Review of patient records 21/31 10 (71) 0 (0) 4 (29) Therapy data for SBC patients (4 patients had alkylating CTX)
Alm El-Din 2009 [54] USA 1964-2001 Single institution cohort study Review of patient records 21/31 130 (52) 24 (67) 0 (0) 0 (0) 118 (48) 12 (33) First raw: therapy data for all patients (26% had alkylating CTX) Second raw: therapy data for SBC (22% had alkylating CTX)
Hudson 1998 [29] USA 1968-1990 Single institution Review of patient records 21/30 116 (30) 15 (4) 256 (66) Therapy data of M + F HL patients
Gervais-Fagnou 1999 [31] Canada 1965-1990 Single institution cohort study (HL Dx. at ≤30y) Review of patient records 22/30 225 (55) 0 (0) 186 (45) Therapy data of M + F HL patients
Munker 1999 [32] Germany 1974-1994 6 institutions cohort study Munich tumor registry, patient records, and patient & family contact 24/31 484 (43.1) 169 (15.1) 464 (41.4) Therapy data of M + F HL patients (8/9 SBC patients received RT)
Green 2000 [34] USA 1960-1989 Single institution cohort study (HL ≤20y at Dx.) Patient records and mail contact 24/30 1 (25) 0 (0) 3 (75) Therapy data for SBC patients
Swerdlow 2000 [36] United Kingdom 1963-1993 BNLI (cohort study) BNLI + 2 cancer databases 24/31 1449 (27) 1693 (31) 2327 (42) Therapy data of M + F HL patients (all SBC had RT)
Swerdlow 2011 [62] United Kingdom 1963-2001 BNLI (cohort study) BNLI database (70 institutions) 25/31 0 (0) 2366 (41) 3432 (59) Therapy data of M + F HL patients (SBC: 14% CTX only, 86% CTX + RT)
Cellai 2001 [38] Italy 1960-1991 Single institution cohort study Institutional patient records 22/30 546 (36) 325 (21) 653 (43) Therapy data of M + F HL patients (SBC patients: 6% RT, 94% RT + CTX)
Neglia 2001 [39] USA and Canada 1970-1986 25 institutions (CCSS) cohort study (≤21y at HL Dx., 5-y survivors) Institutional patient records 26/32 NR NR NR Therapy data were reported for all children malignancies combined
Kenney 2004 [45] USA and Canada 1970-1986 Same as Neglia et al. [40] Institutional patient records 26/32 NR NR NR Therapy data were reported for all children malignancies combined
Castellino 2011 [59] USA and Canada 1970-1986 Same as Neglia et al. [40] and Kenny et al. [46] Institutional patient records 26/32 263 (33) 46 (6) 472 (60) Therapy data for all HL female patients
Foss Abrahamsen 2002 [40] Norway 1968-1985 Single institution cohort study (HD ≥ 1y survivors) National cancer registry 21/30 447 (44) 202 (20) 363 (36) Therapy data of M + F HL patients
Bhatia 2003 [42] USA and Europe 1955-1986 15 institutions cohort study Institutional patient records 26/33 314 (23) 14 (47) 106 (8) 0 (0) 960 (69) 15 (53) First raw: therapy data of M + F HL patients Second raw: therapy data of SBC patients
Wahner-Roedler 2003 [44] USA 1950-1993 Single institution cohort study Institutional patient records 23/31 322 (50) 23 (77) 0 (0) 0 (0) 327 (50) 7 (23) First raw: therapy data of M + F HL patients Second raw: therapy data of SBC patients
Behringer 2004 [60] Germany 1981-1989 Multi-Institutional cohort study German HL database 23/31 675 (12.9) 618 (11.8) 3947 (75.3) Therapy data of M + F HL patients
Guibout 2005 [46] UK and France 1954-1985 8 institutions cohort study Institutional patient records 28/32 28 (23) 9 (7) 86 (70) Therapy data of M + F HL patients
Taylor 2007 [51] UK 1940-1991 PBCS National Registry of Childhood Tumors 22/31 121 (37) 7 (44) 63 (20) 0 (0) 138 (43) 9 (56) First raw: therapy data of female HL patients Second raw: therapy data of SBC patients
Basu 2008 [52] Constine 2008 [53] USA 1960-1990 5 institutions cohort study (<19y at HL Dx.) Institutional patient records 22/31 174 (44) 18 (62) 37 (9) 3 (10) 187 (47) 8 (28) First raw: therapy data of M + F HL patients Second raw: therapy data of SBC patients
Howell 2009 [56] UK 1965-2008 Cohort from a registry and single institution Institutional patient records and a registry data 27/31 6 (26) 0 (0) 17 (74) Therapy data of SBC patients
Inskip 2007 [61] USA 1973-2002 PBCS (< 18y at Dx) SEER database 29/31 NR NR NR  
  1. *Absolute excess rate of SBC incidence cases per 10,000 person-years of follow-up.
  2. CI confidence interval, Cum. Cumulative, DCIS ductal carcinoma in-situ, HL Hodgkin’s lymphoma, MF males and females, NR not reported or data could not be calculated, O/E observed/expected, RR relative risk, SBC second breast cancer (unless indicated, all are invasive breast cancer), y year. (Studies shaded together represent overlapping data).
\